FXYD6-FXYD2

Across TCGA pan-cancer cohorts, FXYD6-FXYD2 RNA is linked to patient survival in 1 of 34 cancer types, making it the most broadly survival-associated FXYD6-FXYD2 data layer.

The strongest signal is observed in small cell lung cancer (SCLC), where higher FXYD6-FXYD2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated FXYD6-FXYD2 expression acts as an unfavorable survival marker, although some lineages such as SCLC show a favorable association.

SCLC are the cancer types where FXYD6-FXYD2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Tertile	II,III,IV	0.584	0.186	.003	37	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

FXYD6-FXYD2–SCLC (DFS)

Open the SCLC breakdown →